메뉴 건너뛰기




Volumn 54, Issue 7, 2010, Pages 3018-3020

Drug resistance mutations in HIV-infected patients in the Spanish drug resistance database failing tipranavir and darunavir therapy

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; DARUNAVIR; FOSAMPRENAVIR; FOSAMPRENAVIR PLUS RITONAVIR; LOPINAVIR; TIPRANAVIR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; PYRIDINE DERIVATIVE; PYRONE DERIVATIVE; SULFONAMIDE;

EID: 77953793261     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00160-10     Document Type: Article
Times cited : (8)

References (15)
  • 2
    • 33750338185 scopus 로고    scopus 로고
    • Genotypic changes in HIV-1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir
    • Baxter, J., J. Schapiro, C. Boucher, V. Kohlbrenner, D. Hall, J. Scherer, and D. L. Mayers. 2006. Genotypic changes in HIV-1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir. J. Virol. 80:10794-10801.
    • (2006) J. Virol. , vol.80 , pp. 10794-10801
    • Baxter, J.1    Schapiro, J.2    Boucher, C.3    Kohlbrenner, V.4    Hall, D.5    Scherer, J.6    Mayers, D.L.7
  • 7
    • 33746576313 scopus 로고    scopus 로고
    • Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1 infected patients at 48 weeks in the randomized evaluation of strategic intervention in multidrug resistant patients with tipranavir (RESIST studies): An analysis of combined data from two randomised open-label trials
    • the RESIST Investigator Group
    • Hicks, C., P. Cahn, D. Cooper, S. Walmsleg, C. Katlama, B. Clotet, A. Lazzarin, M. A. Johnson, D. Neubacher, D. Mayers, H. Valdez, and the RESIST Investigator Group. 2006. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1 infected patients at 48 weeks in the randomized evaluation of strategic intervention in multidrug resistant patients with tipranavir (RESIST studies): an analysis of combined data from two randomised open-label trials. Lancet 368:466-475.
    • (2006) Lancet , vol.368 , pp. 466-475
    • Hicks, C.1    Cahn, P.2    Cooper, D.3    Walmsleg, S.4    Katlama, C.5    Clotet, B.6    Lazzarin, A.7    Johnson, M.A.8    Neubacher, D.9    Mayers, D.10    Valdez, H.11
  • 9
    • 55049134097 scopus 로고    scopus 로고
    • Resilience to resistance of HIV-1 protease inhibitors: Profile of darunavir
    • Lefebvre, E., and C. Schiffer. 2008. Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir. AIDS Rev. 10:131-142.
    • (2008) AIDS Rev. , vol.10 , pp. 131-142
    • Lefebvre, E.1    Schiffer, C.2
  • 10
    • 33747122063 scopus 로고    scopus 로고
    • Protease mutations associated with higher or lower than expected tipranavir susceptibility based on the TPV mutation score
    • abstr. 637
    • Parkin, N., and C. Chappey. 2006. Protease mutations associated with higher or lower than expected tipranavir susceptibility based on the TPV mutation score, abstr. 637. 13th Conference on Retroviruses and Opportunistic Infections, Denver, CO.
    • (2006) 13th Conference on Retroviruses and Opportunistic Infections, Denver, CO
    • Parkin, N.1    Chappey, C.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.